| Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
|---|---|---|---|---|---|---|
| 2015 | Measuring quality of life in patients with head and neck cancer: Update of the EORTC QLQ-H&N Module, Phase III | Singer S.; Ara?jo C.; Arraras J.I.; Baumann I.; Boehm A.; Brokstad Herlofson B.; Castro Silva J.; WEI-CHU CHIE ; Fisher S.; Guntinas-Lichius O.; Hammerlid E.; Irarr?zaval M.E.; Jensen Hjermstad M.; Jensen K.; Kiyota N.; Licitra L.; Nicolatou-Galitis O.; Pinto M.; Santos M.; Schmalz C.; Sherman A.C.; Tomaszewska I.M.; Verdonck De Leeuw I.; Yarom N.; Zotti P.; Hofmeister D. | Head and Neck | 53 | 45 | |
| 2017 | A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator's choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141 | Kiyota N.; Hasegawa Y.; Takahashi S.; Yokota T.; Yen C.-J.; Iwae S.; Shimizu Y.; RUEY-LONG HONG ; Goto M.; Kang J.-H.; Sum Kenneth Li W.; Ferris R.L.; Gillison M.; Namba Y.; Monga M.; Lynch M.; Tahara M. | Oral Oncology | 73 | 63 | |
| 2020 | Two-year follow-up of a randomized phase III clinical trial of nivolumab vs. the investigator's choice of therapy in the Asian population for recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141) | Yen C.-J.; Kiyota N.; Hanai N.; Takahashi S.; Yokota T.; Iwae S.; Shimizu Y.; RUEY-LONG HONG ; Goto M.; Kang J.-H.; Li W.S.K.; Ferris R.L.; Gillison M.; Endo T.; Jayaprakash V.; Tahara M. | Head and Neck | 20 | 16 |
